pharma-and-clinical-pharmacy-congress-2016_keynote

3 / 6

Volume 5 Issue 4(Suppl) Clin Pharmacol Biopharm
ISSN: 2167-065X CPB, an open access journal
Page 21
Pharma & Clinical Pharmacy Congress 2016
November 07-09, 2016
conferenceseries.com
November 07-09, 2016 Las Vegas, Nevada, USA
4th International
Pharma & Clinical Pharmacy Congress
Monika I Konaklieva, Clin Pharmacol Biopharm 2016, 5:4(Suppl)
Molecular targets of b-lactams-beyond the usual suspects
b-Lactams have historically been viewed as a class of antimicrobials. However, this paradigm is shi ing towards a focus
on their ability to function as inhibitors of bacterial enzymes, particularly those involved in broad-spectrum b-lactam
resistance, i.e., extended spectrum b-lactamases (ESBL). is shi in focus is the result of the recognition of the b-lactam’s
ability to acylate enzymes, the majority of which have serine as nucleophile in the active site. In addition to being inhibitors
of bacterial enzymes, b-lactams also inhibit viral and mammalian serine enzymes demonstrating inter-kingdom activity. e
focus of this presentation is on the evaluation of the potential of b-lactam antibiotics as inhibitors of the serine enzymes of both
prokaryotic and eukaryotic origin, with speci c focus on the structure-function relationship of b-lactams as antimicrobial and
antineoplastic agents.
Biography
Monika Konaklieva completed her PhD in Chemistry - Organic Synthesis from SUNY Buffalo -1997, and became a visiting professor in Medicinal Chemistry at
Midwestern University, Chicago, Illinois (1997-1999). She is currently an Associate Professor at American University. She has published more than 40 papers in
reputed journals and has been serving as an editorial board member of several chemistry journals publishing in the areas of organic and medicinal chemistry.
Monika I Konaklieva
American University, USA